vimarsana.com
Home
Live Updates
Aeglea BioTherapeutics Presents Additional Data from PEACE P
Aeglea BioTherapeutics Presents Additional Data from PEACE P
Aeglea BioTherapeutics Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at SIMD
/PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to...
Related Keywords
Texas ,
United States ,
Aeglea Biotherapeutics ,
Deric Bradford ,
Anthonyg Quinn ,
Society For Inherited Metabolic Disorders ,
Drug Administration ,
European Medicines Agency ,
Prnewswire Aeglea Biotherapeutics Inc ,
Nasdaq ,
Laboratory Measure ,
Inherited Metabolic Disorders ,
Annual Meeting ,
Patient Level Outcomes ,
Gross Motor Function Classification System ,
Score Range ,
Additional Secondary Efficacy Endpoints ,
Baseline Relative ,
About Pegzilarginase ,
Rare Pediatric Disease ,
Breakthrough Therapy ,
Fast Track ,
Orphan Drug ,
Orphan Drug Designation ,
European Medicines ,
Nc ,